Cancer is one of complex diseases that are a big threat to mankind ' 
Introduction
Cancer is a complex disease that is largely driven by many somatic mutations gradually accumulated during the lifetime of an individual. It can change person's DNA structure or genome. As we know, infinite proliferation is a feature of cancer cells, and another dreadful feature is that it can spread to others through blood circulation and lymphatic system [1] . These mutations are divided into single nucleotide variants substitutions (SNVs), small indels, larger copy number aberrations (CNAs), structural aberrations (SVs) which is also called large-genome rearrangements, and so on. Numerous experimental works have identified lots of driver genes or pathways, which have dramatically expanded our knowledge about somatic mutations in cancer, such as The Cancer Genome Altas (TCGA). More importantly, some mutations have been successfully applied into medical treatment. For example, Imatinib has been used to target cells expressing the BCR-ABL fusion gene in chronic myeloid leukemia [2, 3] , and Gefitinib is therapeutic to inhibit the epidermal growth factor receptor in lung cancer [4] . However, there are lots of works should be done because we have few knowledge about most cancer.
Generally, the somatic mutation can be divided into two types in another criterion: one is called as passenger mutation that has accumulated in somatic cells but has no influence to cell proliferation in cancer, and the other is driver mutation which is important for cancer development, and can promote the cancer cell to proliferate infinitely and diffuse slowly into other organs. A major challenge in finding mutated driver pathways in cancer is to distinguish driver mutations which are our target from sporadic passenger mutations. The methods for identifying mutated driver pathways, therefore, are needed urgently. Based on previous research, the study process mainly includes recurrent mutations and pathways study.
A variety of approaches have been developed for finding driver genes or pathways in cancer so far. One model to find driver mutations is to identify genes that are mutated at significant frequencies in a lot of cancer patients. To put it simply, lots of work about the driver gene problem focus on a single gene. The original method for finding driver gene is to identify recurrent mutations. There is a phenomenon that some cancer genes are mutated at high frequency (such as TP53), while some cancer genes are mutated at much lower frequency. The approach contains two difficulties: First, it is a challenge to get a reasonable estimate of the back ground mutation rate (BMR), because the rate of somatic mutation and selection or clonal amplification in the somatic evolution of a cancer should be both taken into account, but it is hard to obtain these data. Second, each of pathways contains more than one gene, and there are lots of combinations of driver mutations that play a key role in cancer. Mutational heterogeneity complexes the calculating work and it is difficult to distinguish passenger genes from driver genes in cancer [5] . In addition, testing the recurrence of individual mutations requires examining mutations which are part of cellular signaling and regulatory pathways. The method need prior knowledge, but the known pathways in database are incomplete. Because the superposition of all components in a pathway and the useful information for special cell types are incomplete so far, the method for identifying recurrent mutations are not efficient methods to measure the importance of a gene, particularly large cancer samples.
Compared with the approaches mentioned above, we should consider the combinations of mutations and find or develop new algorithms to discover driver pathways without relying on prior knowledge. Meanwhile, it is necessary to hold the point that we should consider the problem in pathway level rather than in gene level. Three approaches [2] have been used to solve the problem: Firstly, identify combinations of recurrent mutations in pre-defined gene sets which come from the databases of known pathways, e.g., Recurrent Mutually Exclusivity (RME) [6] method focus on building sets of genes from cancer data. Secondly, identify the driver genes or pathways through the genome-scale interaction networks, e.g., the approach Mutual Exclusivity Modules (MEMo) [7] proposed by Ciriello et al. find modules by considering mutual exclusivity between mutations for pair of genes that have recorded interactions in a protein interaction network. Thirdly, De novo algorithms are introduced to solve the so-called maximum weight submatrix problem. More recently, Vandin et al. developed De novo Driver Exclusivity (Dendrix) [8] to identify the driver genes and pathways with high coverage and mutual exclusivity feature. With the hypothesis that each driver pathway contain approximately one driver mutation per patient and an important driver pathway should be mutated in many patients promoted by Raphael etc., the problem has changed to be focused on solving the maximum weight submatrix problem.
The submatrix problem was designed by Vandin et al. It was developed to de novo discover a single mutated driver pathway from mutation data. A weight function was introduced by combining the coverage and exclusivity features they proposed: high coverage-most patients have at least one mutation the set; high exclusivity-nearly all patients have no more than one mutation in the set [8] . They define a measure on set of genes that quantifies the genes which satisfy the two features. Before the Dendrix algorithm, they have tried the greedy algorithm. When the algorithm is given a sufficiently large number of patients, the results shows an optional solution.
For Dendrix, they develop Markov chain Monte Carlo (MCMC) algorithm because of these statistical assumptions is too restrictive for some data, and the number of patients in currently available data sets are not incomplete. MCMC approach sample sets of genes according to a distribution that gives significantly higher probability to set of genes with high coverage and exclusivity features. It is a well-established technique to sample from combinatorial spaces. What's more, they think that this problem is computationally difficult to solve. The problem is too restrictive for analysis of real somatic mutation data.
In recent years, several studies have made contributions to solve the maximum weight submatrix problem [8, 9] : considering mutation data from cancer patients, they create a mutation matrix A with m rows and n genes, where each row is a patient and each column represents a gene. The corresponding entry in row i and column j is equal to 1 if gene j is mutated in patient i. In our study, we compare Dendrix, Simple Genetic Algorithm (SGA) and Multi-population Genetic Algorithm (MPGA) onto several data. It is well known that the Markov chain Monte Carlo (MCMC) using in Dendrix and the SGA algorithm are stochastic algorithm. They are easily trapped in local optimal solution or sometimes it cannot find some driver genes and pathways. Besides, SGA method always has the premature phenomenon and slow convergence deficiencies and the appropriate mutation rate is hard to define.
In order to overcome the problem inferred above, we combine MPGA algorithm and chaos algorithm advantages to improve the stability of these methods. In this way, the population diversity can be increased and the premature phenomenon might be avoided. The MPGA method divides populations into subpopulations. Among the subpopulations, the information of subpopulations can be exchanged through immigration. For example, some excellent individuals can be exchanged among the subpopulations to improve population diversity. Meanwhile, by importing the chaos operator, it has overcome the defect of precocity for SGA, for its particularly inherent randomness and ergodicity to skip the local optimization. The experimental results on several datasets indicate that our approach can find more relevant genes and can improve the stability of identifying driver genes and pathways in a certain degree.
Methods

The Problem
Driver mutations occur in minority genes, while passenger mutations occur randomly across all genes. As Vandin et al. introduced, we can identify the driver genes in × binary mutation matrix with two features: high coverage and mutual exclusivity. They defined the coverage overlap as follows.
The maximum weight submatrix problem turns into measuring the trade-off between coverage and exclusivity, the weight scoring function is described as below.
This problem is NP-hard problem [8] . ( ) = { : = 1} means the corresponding gene g is mutated in the matrix. Similarly, for a set M of genes, ( ) = ∪ ( ) denote the set of patients in which at least one of genes in M is mutated and W(M) measures the coverage overlap of M [8] . As a result, the solution of the problem turns to be finding a submatix with higher weight value W.
Main Process of MPGA
MPGA simulates natural processes, such as selection, recombination, mutation, migration. Its individuals are selected according to their fitness function defined as the weight function W in Eq. (2) . Selection means which individuals are chosen for mating or recombination and it is a preparation stage for mutation. In general, rank-based fitness assignment behaves in a more stable way than proportional fitness assignment, so we chose the rank-based fitness assignment in our approach. The migration model divides the populations into multiple subpopulations and it is a divide and conquer algorithm. For a certain number of generations, these subpopulations evolve independently from each other and then the migration will be distributed between the subpopulations. After recombination every offspring will be mutated in a low probability. We randomly alter one variable value with 1 to 0 and another variable value with 0 to 1 oppositely. When the chaos variables are put into practice to achieve chaos optimal search, there is no doubt that this algorithm will be much more superior to random search for its inherent ergodicity to skip the local optimization.
Additionally, because the chaos algorithm has the ergodic advantage, when we generate initial population, the chaos operator could be used in the process. We have used Logistic model to sample, and the parameter = 4. Figure 1 shows a brief structure of MPGA. MPGA works on populations of individuals instead of single solutions, which means that the process of MPGA can be designed in a parallel way. Individuals are selected according to their fitness. Parents are recombined to produce offspring. All offspring then will be mutated, and calculate the fitness of offspring. After producing a new generation, the immigration will be transformed among the subpopulations.
The cycle is performed until the max weight is reached. Genetic Algorithm is powerful and performs well on a broad class of problems, but the stability of the approach need to be increased. The MPGA simulates the evolution of a species in a way just like the evolution of the nature in our real life. With individuals are exchanged between the subpopulations, MPGA can get better performance. The procedure of MPGA is described as follows.
1) Set the parameter of the program, i.e., the number of population , population size , mutation rate , iteration of the algorithm , and submatrix size .
2) Generate initial population. In each iteration, it will generate initial populations, here we will adopt chaos operator to sample, and each population is selected from the current population based on the selection probability, and generates offspring through recombination. 4) Each offspring may optionally be mutated with a certain probability .
5) All individuals are ranked according to their weight scoring value. The best result will be treated as the next generation which is used as the current population in the subsequent iteration.
6) Repeat 2-5 steps until the termination criterion is satisfied.
Experiments
Simulated Mutation Data
We first compared MPGA to SGA and Dendrix on simulated data. In general, because of the stochastic of approaches, these may not get the best solution in a run. So we could measure the stability of these approaches in two features: average score and well-run. Average sore (Z) is the result of dividing the sum of max weight by total number of runs (N), represents the sum of max weight pathways in a run. Well-run means the run of an approach that can find the max weight pathway.
where represents the weight value of the -th run. There are two ways to evaluate the stability performance of these methods. One way is the comparison of average score, and the other way is counting the well-runs of one known pathway with plenty of runs. In our experiments, the results can be divided into two situations according to the number of pathways with max weight value: single pathway case and multi pathways case. Average score feature adapts to both cases mentioned above.
In order to guarantee the fair comparison, the total number of individuals should be equal in each subpopulation. In experiments, the parameters are set as: =20, =30*floor(n/100), =0.008, and =2000. The experimental results are described in Tables 1-6 . Table 1 and Table 2 show the results comparison of Dendrix, SGA and MPGA on simulated mutation data in different samples (S). The average score of these methods are compared varying with the number of runs. Here we considered both cases mentioned above. Overall, it is easy to know the performance of our method is higher than others, which means our method can identify the pathway efficiently. Secondly, MPGA identify the max weight pathway with great probability, while other methods even could not get the solution, which is the obvious difference among these methods. For example, MPGA can identify a pathway whose max weight value W is 35 when S=48 and find a pathway whose max weight value equals to 58 when S=90. However, Dendrix could not get it.
As discussed before, there is a situation that multi-pathways correspond to the same weight score. For MPGA, it can identify lots of max weight pathways, while other methods run with higher randomness and could not get the driver pathway in some cases. For example, when S=86, MPGA can identify 4 pathways with the same max weight value, SGA always can find one or two pathways, Dendrix performance is worse than SGA. Such phenomenon lies in the instability of MCMC and SGA. As shown in Table 2 , MPGA's average score is the highest among these methods. As a whole, MPGA achieves our goal and is a much more stable method for identifying driver pathway in cancer. Figure 2 shows the change of well-runs in different samples. We calculate the available runs in a test. For example, if we run the program 50 times, and we found 36 of them can identify the max pathway, we took the 36 as well-runs. It is easy to know MPGA runs with high performance from Figure 2 . In summary, when the samples are large, the corresponding well-runs will be higher. Just as shown in Figure 2 , the results of subplot B is larger than A. In addition, when samples are small, MPGA also can identify max weight pathways with high performance. In summary, the approach MPGA achieves our goal and is a much more stable method for identifying driver pathway in cancer.
Lung Cancer Data
Then we applied MPGA onto lung cancer, glioblastoma (GBM), Head and neck squamous cell carcinoma (HNSCC) and ovarian data. The lung data is consists of 163 rows and 346 columns [8] . The average score and well-run features as compared for each method. From Table 3 , the results are similar and show that these methods run with good performance. When the parameter k = 3, the max weight value in our experiments is 32. The performance in these methods is close. Because on the one hand, the data is small, on the other hand, the max weight pathway is single. From Table 2 , the results are similar to results on the data before. Here when we set S =120, and find MPGA can identify 7 or 8 max weight pathways. SGA can identify 6 pathways on average. Specially, we find that MPGA even get the whole well-runs in some case. From this experiment, we began to discover that Dendrix and SGA depend more on data type or structure than MPGA. It is a disparity among them in other cases. In some case, these results are close. Above all, from another aspect we deduce that MPGA are more applicable to different cancer data. Figure 3 shows part of pathway in lung cancer. Gene sets (EGFR, KRAS, and STK11) and (ATM, TP53) can be discovered. Because EGFR, ATM, TP53, KRAS, and STK11 are famous driver gene in lung cancer. When we remove (EGFR, STK11, KRAS, ATM, TP53) and set k=5 (k is number of genes in M), we identify a pathway (CDKN2A, GNAS, LRP1B, NF1 and NTRK3) whose weight value is 44. CDKN2A and NTRK3 are driver genes in lung cancer to control cell cycle [10] . GNAS play an important role in calcium signaling pathway. NF1 can lead to neurofibromatosis. As shown in Figure 4 , the performance of SGA and MPGA is close when S is the max value 163. The trend of subplot A and B is similar. When the samples are large, the corresponding well-runs will be higher. The value of subplot B is larger than A. In subplot A, the well-runs value is clearly greater than other methods. As a whole, the performance of MPGA is superior to SGA. There is a phenomenon that the famous driver gene or pathway of lung cancer is easy to identify.
Glioblastoma Cancer Data
The glioblastoma dataset is downloaded from bioinformatics [11] . After processing the dataset, we got a mutation matrix with 90 samples and 1126 genes through an excel file, Then we can run our program with the file. Here we set the iteration nger=1000, number of child population =20, the number of individual in one population =25, and =3. When =84, we ran the MPGA, and can get the max weight ( ) = 62. When =44, the result ( ) = 34, corresponding 3 max weight ways. Many experiments are carried out in our research. The results are described below. The results are similar to the results of simulated data ( Table 4) .
As shown in Table 4 , MPGA can get the highest score, while the Dendrix run with the lowest results and it depends on the samples highly. The average weight values of MPGA, SGA, Dendrix are about 56, 47, 33 in Table 4 , respectively. So the performance of these approaches are ranked like MPGA > SGA > Dendrix. It is a good idea that we identify more feasible solutions as soon as possible, and solve it with additional information, such as gene expression data [11] . In real mutation data, there are multiple optimal solutions. In addition, because of the noise in the data or other factors, the max weight pathway may not be the best one in biological mutation data. So we should identify more feasible solutions as soon as possible.
Similarly, we divide it into two conditions: S=84 and S=44, and then compared the stability of finding the optimal pathway (CDKN2B, RB1, CDK4) [8] . Both we checked the well-runs of each method varying with the number of samples. Firstly, we run the methods based on two loops, the times of outer loop is 5, and the inner loop is {10, 50, 100, 1000, 1500, 2000}, then calculate their average results for each case. Generally, the results are similar to the experiments on simulated data. In addition, when the samples S=44, the MPGA's performance is much better than other methods. In other words, this phenomenon shows MPGA is also efficient even in small sample data. As shown in Table 4 , the smaller the samples are, the higher difference among these methods you get. The value are ranked as MPGA>SGA>Dendrix. The result clearly shows that MPGA successfully avoids trapping in local optimal solution and is much more applicable to different samples.
Besides, when the famous driver genes (CDK4, CDKN2B, TSPAN31, RB1, and TP53) and the metagene CYP27B1 are moved, on the remaining genes, we set k = 5, then run the MPGA and find three pathways whose weight are 50, including 6 genes totally. Other than ERBB2, the rest genes (EGFR, GRIA2, PIK3CA, PIK3R1, and PTEN) play an important roles in glioblastoma cancer [11] [12] [13] . The identified known pathways are shown in Figure 5 .
Head and Neck Squamous Cell Carcinoma Data
HNSCC is the sixth most common deadly cancer in the world. The survival rates for many HNSCC patients have made little increase over the past 40 years [14] . This mutation data matrix includes 74 rows and 4920 columns, which is sparse.
Some significantly mutated genes had previously been detected in HNSCC data, such as TP53, TTN, and CDKN2A. TP53 and TTN are mutated in the majority (46/74), (23/74) of samples respectively. Therefore we remove the genes TP53 and TTN because of the prevalence of mutation [11] . When k=3, we get gene set (CDKN2A, PCLO, SYNE1). SYNE1 was observed in 8% of HNSCC samples, it have been implicated in the regulation of nuclear polarity. PCLO mutation was seen in 12% of cases, and it is important for terminal squamous differentiation [14] . When k=7, we got the max weight W=46. MPGA can identify 7 optimal pathways. NOTCH1 mutations have been reported that it occurs in 10% to 15% of head and neck squamous cell carcinomas. The result of the paper [15] shows a bimodal pattern of NOTCH pathway transformations, which will be more suitable for HNSCC treatment (Figure 6 ). As we did above, we also carried out the same experiments on HNSCC data. Unlike the results on lung cancer data, the performance of these methods are similar to the results on simulated data. This phenomenon demonstrates that the performance of these methods is similar.
Ovarian Carcinoma Data
The data comes from bioinformatics [11] . They have analyzed messenger RNA expression, microRNA expression, promoter methylation and DNA copy number aberrations [16] . The data matrix covers 313 samples and 5385 genes.
We also applied the MPGA algorithm onto ovarian carcinoma patients from The Cancer Genome Atlas (TCGA, 2011). The experiments are similar to the results of HNSCC data. TP53 is mutated in 251 patients and the analysis of gene TTN shows that the mutations of it are more likely artifacts [11, 16] . We ran the MPGA algorithm with the range of k (2≤k≤10). For k=2, we find the gene set (CCNE1, MYC), they are key genes in ovarian cancer; for k=3, the optimal gene set is CCNE1, MYC, and NINJ2. They play an important role in the ovarian carcinoma. After removing the above genes, when k=4, we identify a set of four mutation groups (KRAS, PPP2R2A, PRPF6 and RYR2) that is altered in 102/313 of the patients. When k=5, the gene set (KRAS, MAPK8IP2, NF1, MUC16, STMN3) is identified. 
Figure 7. Part of MAPK Signaling Pathway in Ovarian Cancer
It is well known that KRAS, NF1 and MAPK8IP2 are part of MAPK signaling pathway ( Figure 7 ). The mutation of STMN3 is related to malignant progression of multiple cancer types [17] . The abnormal of STMN3 can affect multiple cancer and play a key role in EMT. The mutation of MUC16 is related to Wnt signaling pathway, and play an important role in ovarian carcinoma [18] . Thus, MPGA can identify extra pathways and shows stable performance.
Conclusions
This study mainly focus on some of the challenges in finding driver mutations and driver genes in cancer. We discuss several computational approaches that are used to detect somatic mutations and pathways in our research. With the development of largescale cancer sequencing projects, the rapidly computational identification method of driver mutations is needed urgently. It could be an important step in determining patient prognosis and treatment.
Dendrix is a Markov Chain Monte Carlo (MCMC) algorithm that samples sets of k genes according to their submatrix weight value W. While the MCMC algorithm could not identify optimal gene sets in some cases. sMPGA can also produce sets with strictly larger weight. What's more, there are a variety of cases might occur. Firstly, there may be multiple gene sets with maximum weight on a run, while SGA only finds part of them. Secondly, what the SGA identified in a run may not be the optimal solution when considered in isolation or the algorithm is stochastic. While MPGA can basically find all of these feasible solutions on real somatic mutation data. As a result, MPGA is much more stable method for identifying driver pathway in cancer.
The maximum weight submatix problem model has its limitation that the model could not integrate biological information effectively. Therefore our future work may combine the interaction network model with the max weight submatirx model to design a new model to discover the fact hiding in cancer data.
